Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Oxford BioMedica plc

https://www.oxb.com/

Latest From Oxford BioMedica plc

China Biotech CEO Interview: Starting A CNS Venture In An Economic Downturn

From Wyeth/Pfizer to Jiangsu Hengrui to IMab to starting her own biotech, Joan Huaqiong Shen has seen many ups and downs of drug development in China. She sat down with Scrip on the sidelines of the recent DIA China meeting to discuss her latest startup devoted to novel small molecules to treat schizophrenia and epilepsy and a gene therapy for ALS.

China Research & Development

BIOSECURE Act Diluted Significantly, But China Plus Strategy Still Accelerating: Strides MD

A time extension to US companies to shift business away from a few Chinese firms under the proposed BIOSECURE Act has disappointed the Strides MD. However, the China plus strategy continues to drive business and capacity expansion for auto-injectors required by GLP-1 customers is expected

Commercial Business Strategies

China, EU Regulators Highlight Innovation, Access And Collaboration As Key Policy Aims

Former and incumbent regulatory officials from China and the European Union highlighted the need for supportive regulatory policies for the innovative drug sector at the recent DIA China annual meeting.

China Innovation

US FDA Asked To Tighten China Risk Control By Legislators As Markup Looms

The proposed US BIOSECURE Act is heading to a full committee vote amid heightening tensions, underscored by new US Congressional Oversight Committee letters to the FDA asking it to examine national security threats posed by Chinese 'biotechs of concern.'

United States China
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Gene Therapy, Cell Therapy
  • Other Names / Subsidiaries
    • Oxxon Therapeutics Limited
UsernamePublicRestriction

Register